The British Society for Haematology (BSH) Lymphoma Special Interest Group (SIG) primarily has an educational role. The educational events cover both the clinical aspects of lymphoma diagnosis and management as well as basic scientific and translational science. Lymphoma research will remain the remit of the lymphoma NCRI Lymphoma Clinical Studies Group.
The group organises one educational event every year in autumn, in different geographical locations, and two business meetings per year. A second educational meeting might be held during the ASM, subject to the approval of the BSH Programme Committee.
The SIG committee has 11 elected representatives, members of the BSH, with one reserved position for each of the devolved nations. There are also co-opted members representing specialist nursing, imaging, histopathology and members in training. There are therefore be a total of 15 committee members. It is hoped that there will be even geographical representation but the elected members are all elected on the basis of votes cast without reference to their geographic location except for the reserved positions mentioned above. The Chair is chosen from within the Committee, once elected, during the first business meeting.
Members serve a three year term or less if agreed to allow a staggered rotation.
The BSH Lymphoma SIG offers advice and professional opinion to and through the External Affairs Committee when requested to do so.
Chair: Dr Wendy Osborne
For more information, email [email protected] or call 020 7713 0990.
Join the Lymphoma Special Interest Group.
The SIG welcomes both members and non-members of the BSH who have a special interest in lymphoma and is free to join.
Please note you will need to log in or create a website account to join a SIG.
BSH Lymphoma Podcast
Introduction to the podcast goes here.
Dr Wendy Osborne discusses an approach to the management of patients with early, unfavourable Hodgkin lymphoma focusing on the current evidence, role of PET and the challenges faced by this subgroup of patients.
Dr Wendy Osborne is a consultant haematologist at Newcastle upon Tyne Hospitals NHS Foundation Trust. She has a specialist interest in the field of lymphoma, is a member of the NCRI clinical subgroups looking at high-grade, Hodgkin, and T cell lymphomas, and is the chair of the BSH Lymphoma Special Interest Group.
Dr Wendy Osborne discusses an approach to the management of patients with early, unfavourable Hodgkin lymphoma focusing on the current evidence, role of PET and the challenges faced by this subgroup of patients.
Dr Wendy Osborne is a consultant haematologist at Newcastle upon Tyne Hospitals NHS Foundation Trust. She has a specialist interest in the field of lymphoma, is a member of the NCRI clinical subgroups looking at high-grade, Hodgkin, and T cell lymphomas, and is the chair of the BSH Lymphoma Special Interest Group.
To listen to the podcast, please click Here.
Dr Rory McCulloch discusses clinical management of mantle cell lymphoma, including indolent MCL, upfront management in younger patients, challenges of aggressive blastoid disease and how new therapies may shape treatment algorithms of the future.
Dr McCulloch is a consultant haematologist at Gloucestershire Hospitals NHS Foundation Trust and recently worked as Lymphoma Clinical Research Fellow under Professor Simon Rule at Plymouth University. He was vice-chair of the trainee-led research network HaemSTAR and is a member of the BSH Lymphoma Special Interest Group.
To listen to the podcast please click here.
Dr Shirley D’Sa discusses the management of Waldenström macroglobulinaemia (WM).
Dr D'Sa is a Haematologist and Associate Professor at University College London Hospital NHS Foundation Trust in London, a busy academic centre in Central London, UK, where she also completed her specialist training in haematology. She specialises in the management of patients with IgM-related conditions and paraproteinaemic neuropathies.
She is clinical lead for the UCLH Centre for Waldenström macroglobulinaemia (WM) and Related Disorders, and haematological lead in the Joint Neurohaematology Service alongside the neurology lead, Prof Michael Lunn at the National Hospital for Neurology, Queen Square in London UK.
Dr D’Sa is a co-trustee with patients and colleagues in the UK Registered Charity, WMUK (www.wmuk.org.uk) and the Chief Investigator for the Rory Morrison Registry project for WM and associated conditions which has more than 1200 patients registered from several centres across the UK and a member of the Medical Advisory Panel of Lymphoma Action in the UK.
Dr D’Sa is a CI/PI in several clinical trials in WM and cold agglutinin disease (CAD) and is a committee member on the International Workshops on WM and British Society for Haematology Guidelines Group.
She is a supervisor to successive research fellows in the field of Waldenström and paraproteinaemic neuropathies as well as haematology specialist trainees and undergraduates at UCL Medical School.
To listen to the podcast please click HERE.
Dr Sridhar Chaganti discusses the current management of post-transplant lymphoproliferative disorder (PTLD) including subtypes, prognostic factors and the current treatment options. He explores the role of immunotherapy, cytotoxic agents and the emerging field of cellular therapies in this group of patients.
Dr Chaganti is a consultant haematologist working at University Hospitals Birmingham NHS Foundation Trust. He has a PhD in cancer studies from the University of Birmingham. His research interest is in EBV and lymphomas. His special interests are in haematologic malignancies, lymphomas and stem cell transplantation.
To listen to the podcast please click HERE.